Postmenopausal osteoporosis coexisting with sarcopenia: the role and mechanisms of estrogen

Lu, Lingyun; Tian, Li

doi:10.1530/joe-23-0116

Cited by 27 publications

(4 citation statements)

References 162 publications

(226 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The potential mechanism by which sarcopenia in females with cancer is more sensitive to changes in the NHHR may be related to estrogen. Muscle satellite cells proliferate and differentiate in response to estrogen, thereby increasing muscle mass and strength [ 40 ]. Individuals with cancer often exhibit decreased hormone levels [ 41 ].…”

Section: Discussionmentioning

confidence: 99%

Association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and sarcopenia in individuals with cancer: a cross-sectional study

He,

Ye,

Zhu

et al. 2024

Lipids Health Dis

View full text Add to dashboard Cite

Background Cancer and sarcopenia are both closely related to lipid metabolism, but the relationship between lipid metabolism and patients with cancer and sarcopenia has not been thoroughly studied. The non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) is a reliable measure of lipid metabolism. The purpose of this study was to determine the possible relationship between the NHHR and sarcopenia in individuals with cancer. Methods Data from the National Health and Nutrition Examination Survey (NHANES) database for individuals with cancer, with and without sarcopenia was analyzed using weighted multiple regression equations, weighted regression cubic spline (RCS) analysis, and weighted subgroup analysis. Results In total, 1,602 individuals with cancer were included, of whom 17.1% had sarcopenia. In Adjusted Model 2, the occurrence of sarcopenia was found to be significantly associated with a higher NHHR in cancer (95% confidence interval [CI]:1.01–1.39, P = 0.036). Individuals with high a NHHR had a 2.09-fold higher risk of developing sarcopenia in comparison to those with a low NHHR (95% CI:1.12–3.92, P = 0.022). RCS analysis further identified a U-shaped non-linear relationship between females with cancer and the muscle index. Subgroup analysis indicated that sex was a significant stratifying factor, whereas age, race, marital status, smoking and drinking habits, and history of cardiovascular disease, arthritis, hypertension, and diabetes had no significant impact. Conclusion From the perspective of lipid metabolism, the NHHR may serve as an indicator for monitoring and preventing the occurrence of sarcopenia in individuals with cancer, particularly for females with cancer who appear to have greater sensitivity.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and sarcopenia in individuals with cancer: a cross-sectional study

He,

Ye,

Zhu

et al. 2024

Lipids Health Dis

View full text Add to dashboard Cite

show abstract

“…In postmenopausal women, estrogen levels drop signi cantly, impacting bone and muscle metabolism. This decline in estrogen contributes to osteoporosis and sarcopenia [34]. Men, lacking this hormonal shift, may have a lower risk of severe sarcopenia, highlighting the role of estrogen in muscle health.…”

Section: Gender and Age Differencesmentioning

confidence: 99%

The Role of Medication Literacy and Polypharmacy in Sarcopenia Among Maintenance Hemodialysis Patients: A Cross-Sectional Analysis

Zhu,

Liu,

Yang

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose Sarcopenia is significantly prevalent among maintenance hemodialysis patients, with the contributing factors of medication literacy and polypharmacy receiving limited exploration in current research. This study aims to fill this gap by assessing the impact of these factors, along with demographic and malnurtition, on sarcopenia risk. Methods Conducted at the Wenjiang Hemodialysis Center in West China Hospital, this descriptive cross-sectional study involved 236 participants. Data collection included the Chinese Medication Literacy Scale, Malnutrition-Inflammation Score assessments, bioelectrical impedance analysis, and grip strength measurements, with sarcopenia diagnosed according to the 2019 AWGS criteria. Results The study included 236 participants. Of these, 87 (36.9%) had no sarcopenia, 121 (51.3%) were pre-sarcopenia, 7 (3.0%) were sarcopenia, and 21 (8.9%) had severe sarcopenia. Ordinal logistic regression analysis identified male gender (OR = 0.557, 95% CI: 0.322 to 0.962, P = 0.036), age below 65 (OR = 0.178, 95% CI: 0.082 to 0.389, P < 0.001), and good nutritional status (OR = 0.544, 95% CI: 0.310 to 0.954, P = 0.034) as protective against severe sarcopenia. Conversely, the combination of polypharmacy and limited medication literacy (OR = 1.956, 95% CI: 1.094 to 3.496, P = 0.024) was significantly associated with an increased risk of sarcopenia progression. Conclusion The study highlights the protective role of good nutrition and the lesser susceptibility of males and younger individuals to severe sarcopenia. It underscores the necessity of targeted interventions to address the compounded risk presented by polypharmacy and limited medication literacy in patients undergoing hemodialysis.

show abstract

“…This results in the loss of the balance between bone resorption and formation, in favor of resorption. In addition, the drop in estrogen leads to an increase in the secretion of cytokines (i.e., interleukin-(IL) 6) closely linked to oxidative stress and inflammation but also to osteoclastogenesis [5,6]. All these factors lead to the onset of postmenopausal osteoporosis.…”

Section: Postmenopausal Osteoporosis and Sarcopeniamentioning

confidence: 99%

Irisin and Its Role in Postmenopausal Osteoporosis and Sarcopenia

Falsetti,

Palmini,

Donati

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Menopause, an extremely delicate phase in a woman’s life, is characterized by a drop in estrogen levels. This decrease has been associated with the onset of several diseases, including postmenopausal osteoporosis and sarcopenia, which often coexist in the same person, leading to an increased risk of fractures, morbidity, and mortality. To date, there are no approved pharmacological treatments for sarcopenia, while not all of those approved for postmenopausal osteoporosis are beneficial to muscles. In recent years, research has focused on the field of myokines, cytokines, or peptides secreted by skeletal muscle fibers following exercise. Among these, irisin has attracted great interest as it possesses myogenic properties but at the same time exerts anabolic effects on bone and could therefore represent the link between muscle and bone. Therefore, irisin could represent a new therapeutic strategy for the treatment of osteoporosis and also serve as a new biomarker of sarcopenia, thus facilitating diagnosis and pharmacological intervention. The purpose of this review is to provide an updated summary of what we know about the role of irisin in postmenopausal osteoporosis and sarcopenia.

show abstract

Postmenopausal osteoporosis coexisting with sarcopenia: the role and mechanisms of estrogen

Cited by 27 publications

References 162 publications

Association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and sarcopenia in individuals with cancer: a cross-sectional study

Association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and sarcopenia in individuals with cancer: a cross-sectional study

The Role of Medication Literacy and Polypharmacy in Sarcopenia Among Maintenance Hemodialysis Patients: A Cross-Sectional Analysis

Irisin and Its Role in Postmenopausal Osteoporosis and Sarcopenia

Contact Info

Product

Resources

About